Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT02320656
NA

Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015

Sponsor: Institut Paoli-Calmettes

View on ClinicalTrials.gov

Summary

HEMATO-BIO-IPC-2013-015 is a monocenter prospective longitudinal study. Our aim is to define predictive clinical and biological factors in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by using genomics, genetics and epigenetics, in vitro and in vivo drug sensitivity studies,and translational immonulogy and immunomonitoring studies. HEMATO-BIO primary outcome measure is to identify molecular, genomic and epigenetic, pharmacologic and immunophenotypic alteration in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by collecting, at diagnosis and/or complete remission and/or relapse: * tumor samples: marrow aspiration, blood sampling. * non-tumor samples: skin biopsy, buccal swab . from 650 patients treated at our cancer center.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

650

Start Date

2014-05

Completion Date

2024-10-30

Last Updated

2026-04-21

Healthy Volunteers

No

Interventions

OTHER

Blood sampling

Longitudinal (3 stages of the disease)

OTHER

Bone marrow aspirate

Longitudinal (3 stages of the disease)

OTHER

Skin biopsy

Single biopsy (optional)

OTHER

Buccal swab

Single sampling.

Locations (1)

Institut Paoli-Calmettes

Marseille, France